<--- Back to Details
First PageDocument Content
Type 1 hypersensitivity / Leukotriene antagonists / Respiratory therapy / Respiratory diseases / Allergic rhinitis / Montelukast / Allergy / Atopy / Asthma / Medicine / Health / Allergology
Date: 2013-01-16 03:21:00
Type 1 hypersensitivity
Leukotriene antagonists
Respiratory therapy
Respiratory diseases
Allergic rhinitis
Montelukast
Allergy
Atopy
Asthma
Medicine
Health
Allergology

Add to Reading List

Source URL: www.hkjpaed.org

Download Document from Source Website

File Size: 50,28 KB

Share Document on Facebook

Similar Documents

Reduction of Allergy Symptoms by Molekule’s PECO AIR Purification By: Dr. Nikhil G. Rao Abstract: Exposure to airborne allergens and pollutants is linked to symptom severity for allergic rhinitis and

DocID: 1uuhF - View Document

Medicine / Clinical medicine / Health care / Allergology / Immunology / Immune system / RTT / Allergen immunotherapy / Allergen / Allergic rhinitis / Pollen / Allergy

20160404_Anergis_Closes_CHF_5_Million_Financing_Round_Extension_to_Conduct_the_ATIBAR_Trial

DocID: 1rovF - View Document

Medicine / Immunology / Clinical medicine / Allergology / RTT / Immune system / Food allergies / Allergen / Allergy / Atopy / Allergic rhinitis / Soy allergy

Article ID: WMC005078 ISSNSensitization pattern to food and inhalant allergens in allergic patients from Jeddah city: Saudi Arabia

DocID: 1r2Hj - View Document

Building biology / Medicine / Health / Heating /  ventilating /  and air conditioning / Environmental health / RTT / Air pollution / Occupational safety and health / Indoor air quality / Asthma / Allergic rhinitis / Ventilation

Indoor Air 2008, 17-22 August 2008, Copenhagen, Denmark - Paper ID: 458 The perceived indoor climate in Swedish schools Kjell Andersson*, Inger Fagerlund and Wenche Aslaksen Department of Occupational and Environmental

DocID: 1qgNX - View Document

Medicine / Allergology / Immunology / Clinical medicine / Immune system / RTT / Allergen / Allergic rhinitis / Pollen / Allergy / Rhinitis / Desensitization

Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT − Dose assessment for upcoming Phase III trial EPALINGES, Switzerland, December 11, 2014 – Anergis, a company developing proprietary

DocID: 1q3c9 - View Document